Skip to content
2000
Volume 24, Issue 39
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Angiogenesis refers to the formation of recent blood vessels, which is one of the characteristics of cancer progression and it has been deliberated as a putative target to the treatment of many kinds of cancers. The VEGF signaling substrate is very important for angiogenesis and is commonly high-regulated in tumors. As a result, this molecule has attracted the attention of most of the researchers to develop antiangiogenic therapies. We have presented that VEGF blockage in neoadjuvant setting via bevacizumab, aflibercept and sunitinib not only has revealed some promising benefits but also has shown a large negative outcome in the adjuvant trials. However, at an advanced stage of tumors, suppression of VEGF alone is inadequate to stop advancement, encouraging drug resistance, and probably enhancing metastasis and invasion in the tumor microenvironment, thereby suggesting the therapeutic potential of targeting angiogenic pathways in gastrointestinal cancers.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612825666190110161843
2018-11-01
2025-07-08
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612825666190110161843
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test